


Applicants' Docket No. 101149-1P US  
 Preliminary Amendment dated July 12, 2006  
 Amending a National Phase Filing of PCT/GB2004/03111

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 - 8 (cancelled)

Claim 9 (currently amended) A compound of formula (IA):



in which:

Ar is [[is]] an aryl group, a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, or a bicyclic or tricyclic heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, each of which aryl group or heteroaromatic ring can be optionally substituted by 1-3 groups selected from C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxy, halogen, cyano, CF<sub>3</sub>, OCF<sub>3</sub>, C<sub>3-6</sub> cycloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>2-6</sub> alkenyloxy, hydroxyl, nitro, tosyl, thienyl, benzyl, phenyl, nitrophenyl,

R<sup>1</sup> is hydrogen or C<sub>1-6</sub> alkyl;

X is O, NR<sup>2</sup>, CH<sub>2</sub> or SO<sub>x</sub>

R<sup>2</sup> is C<sub>1-6</sub> alkyl;

x is 0, 1 or 2;

Y is C=O, SO<sub>2</sub>, or (C=O)NH;

Z is (CR<sup>3</sup>R<sup>4</sup>)<sub>r</sub> or Y and Z together form a CH=CH group;

m and n are independently 0, 1, 2 or 3;

p and q are independently 0, 1 or 2;

r is 0, 1, 2, 3, or 4, and

R<sup>3</sup> and R<sup>4</sup> are independently hydrogen or C<sub>1-6</sub>alkyl.


Applicants' Docket No. 101149-1P US  
 Preliminary Amendment dated July 12, 2006  
 Amending a National Phase Filing of PCT/GB2004/03111

Claim 10 (original) A compound according to claim 9 in which Y is C=O.

Claim 11 (currently amended) A pharmaceutical composition comprising a compound of formula (IA) according to Claim 9, or a pharmaceutically acceptable salt or solvate thereof, ~~as claimed in claim 10 or 11~~ in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

Claims 12 - 15 (cancelled)

Claim 16 (currently amended) A method for the treatment of diseases mediated by histamine H3 and H4 receptors comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salts or a solvate thereof:



in which:

Ar is [[is]] an aryl group, a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, or a bicyclic or tricyclic heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, each of which aryl group or heteroaromatic ring can be optionally substituted by 1-3 groups selected from C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxy, halogen, cyano, CF<sub>3</sub>, OCF<sub>3</sub>, C<sub>3-6</sub> cyclolalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>2-6</sub> alkenyloxy, hydroxyl, nitro, tosyl, thienyl, benzyl, phenyl, nitrophenyl,

R<sup>1</sup> is hydrogen or C<sub>1-6</sub> alkyl;

X is O, NR<sup>2</sup>, CH<sub>2</sub> or SO<sub>x</sub>

Applicants' Docket No. 101149-1P US  
Preliminary Amendment dated July 12, 2006  
Amending a National Phase Filing of PCT/GB2004/03111

$R^2$  is  $C_{1-6}$  alkyl;

x is 0, 1 or 2;

Y is  $CH_2$ ,  $C=O$ ,  $SO_2$ , or  $(C=O)NH$ ;

Z is  $(CR^3R^4)_r$  or Y and Z together form a  $CH=CH$  group;

m and n are independently 0, 1, 2 or 3;

p and q are independently 0, 1 or 2;

r is 0, 1, 2, 3, or 4 and

$R^3$  and  $R^4$  are independently hydrogen or  $C_{1-6}$ alkyl.

Claim 17 (currently amended)      The method according to Claim 16 wherein in said compound:

$Ar^1$  is phenyl optionally substituted ~~as defined above. Preferred substituents include halogen~~  
~~such as with~~ iodo, chloro and ~~fluore~~fluoro, cyclohexyl, methyl, ethyl, propyl, t-butyl, ethynyl,  
propenyloxy], hydroxyl, methoxyl, nitro, tosyl, trifluoromethyl, thienyl, benzyl, cyano,  
phenylethynyl, nitrophenyl, methylthio, propoxyl, butoxyl, 2-propenyl, or trifluomethoxyl.

Claim 18 (original)      The method according to Claim 16 wherein in said compound:  
 $R^1$  is hydrogen or methyl.

Claim 19 (original)      The method according to Claim 16 wherein in said compound:  
X is O.

Claim 20 (currently amended)      The method according to Claim 16 wherein in said compound:  
Y is  $CH_2$  or  $C=O$  and Z is  $CH_2$ ,  $CHMe$ ,  $CH_2CHMe$ ; or Y and Z form a  $CH=CH$  group.

Applicants' Docket No. 101149-1P US  
Preliminary Amendment dated July 12, 2006  
Amending a National Phase Filing of PCT/GB2004/03111

Claim 21 (original) The method according to Claim 16 wherein in said compound:  
m is 1 and n is 0.

Claim 22 (original) The method according to Claim 16 wherein in said compound:  
p and q are both 1.

Claim 23 (currently amended) The method according to Claim 16 wherein said  
compound is selected from:

4-(1*H*-Imidazol-4-ylmethoxy)-1-(1-oxo-3-phenylbutyl)-piperidine;  
4-(1*H*-Imidazol-4-ylmethoxy)-1-[[4-(trifluoromethyl)phenyl]acetyl]-piperidine;  
1-[2-(4-Hydroxyphenyl)-1-oxopropyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-piperidine;  
1-[(4-fluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(2-chlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-chlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-(phenylacetyl)-piperidine;  
1-(4-cyclohexylbenzoyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(3,4-dichlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)acetyl]-piperidine;  
1-[(3,4-difluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(2,4-difluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[(4'-propyl[1,1'-biphenyl]-4-yl)carbonyl]-piperidine;  
1-[2-(4-hydroxyphenyl)-1-oxopropyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(2*E*)-3-(3,4-dichlorophenyl)-1-oxo-2-propenyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[3-(2,4-dichlorophenyl)-1-oxopropyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(2,4-dichlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(2-Bromophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(3-Bromo-2-thienyl)methyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-piperidine;  
1-[(3-bromo-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-ethynylphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[[3-(4-methylphenoxy)phenyl]methyl]-piperidine;

Applicants' Docket No. 101149-1P US  
Preliminary Amendment dated July 12, 2006  
Amending a National Phase Filing of PCT/GB2004/03111

4-(1H-imidazol-4-ylmethoxy)-1-[[4-(2-propenyloxy)phenyl]methyl]-piperidine;  
4-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol;  
4-(1H-imidazol-4-ylmethoxy)-1-[(2-methoxyphenyl)methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[[3-(4-methoxyphenoxy)phenyl]methyl]-piperidine;  
1-[(2,3-dichlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(2-chloro-4-fluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-(2-dibenzofuranylmethyl)-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[[2-(methylthio)phenyl]methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-(thieno[2,3-b][1]benzothien-2-ylmethyl)-piperidine;  
1-[(2-chloro-5-nitrophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1H-pyrrole, 2-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-[(4-methylphenyl)sulfonyl]-;  
2-ethoxy-6-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol;  
1-(1,3-benzodioxol-5-ylmethyl)-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[[4-(phenylmethoxy)phenyl]methyl]-piperidine;  
1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-bromophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-(2-thienylmethyl)-piperidine;  
1-[(4-chlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(2-chloro-6-fluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(3-methyl-2-thienyl)methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-(2-naphthalenylmethyl)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-(1-naphthalenylmethyl)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(2-nitrophenyl)methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-(3-thienylmethyl)-piperidine;  
1-([1,1'-biphenyl]-4-ylmethyl)-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(2,5-difluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(3-phenoxyphenyl)methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(3-methylphenyl)methyl]-piperidine;  
1-(2-furanylmethyl)-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(2,6-dichlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;

Applicants' Docket No. 101149-1P US  
Preliminary Amendment dated July 12, 2006  
Amending a National Phase Filing of PCT/GB2004/03111

1-[(4-fluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(3-fluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-(3-furanylmethyl)-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-ethylphenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(2-methylphenyl)methyl]-piperidine;  
1-[(3-chlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(5-methyl-2-thienyl)methyl]-piperidine;  
1-[(4-bromo-2-thienyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(2,2'-bithiophen)-5-ylmethyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
3,5-dichloro-2-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol;  
1-[(3,4-difluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(3,5-difluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-4-(1H-imidazol-4-ylmethoxy)-  
piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[(1-methyl-1H-pyrrol-2-yl)methyl]-piperidine;  
1H-indole, 3-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-(phenylmethyl)-;  
1-[(5-chloro-2-thienyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-(1,3-benzodioxol-4-ylmethyl)-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
2-thiophenecarbonitrile, 3-[[4-[4-(1H-imidazol-4-ylmethoxy)-1-  
piperidinyl]methyl]phenoxy]methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[[5-(phenylethynyl)-2-thienyl]methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[[5-(4-nitrophenyl)-2-furanyl]methyl]-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[[5-(3-nitrophenyl)-2-furanyl]methyl]-piperidine;  
1-[(4-chloro-1H-pyrazol-3-yl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-bromo-1-methyl-1H-pyrazol-3-yl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-bromo-1H-pyrazol-3-yl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
2-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-benzonitrile;  
4-(1H-imidazol-4-ylmethoxy)-1-[(4-iodophenyl)methyl]-piperidine;  
1-[(5-ethyl-2-thienyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;  
4-(1H-imidazol-4-ylmethoxy)-1-[[5-(methylthio)-2-thienyl]methyl]-piperidine;  
1-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methyl]-4-(1H-imidazol-4-ylmethoxy)-piperidine;

Applicants' Docket No. 101149-1P US  
Preliminary Amendment dated July 12, 2006  
Amending a National Phase Filing of PCT/GB2004/03111

1-[[1-(4-chlorophenyl)-1*H*-pyrrol-2-yl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(phenylethynyl)-2-thienyl]methyl]-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-phenoxy-2-thienyl)methyl]-piperidine;  
1-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-propoxyphenyl)methyl]-piperidine;  
2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol;  
1-[(2,4-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-2-thiophenecarbonitrile;  
1-(benzo[*b*]thien-3-ylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
2-chloro-3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-pyridine;  
3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-2-(2-propenyl)-phenol;  
1-[(4-chloro-3-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(trifluoromethoxy)phenyl]methyl]-piperidine;  
1-[(2,6-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-bromo-2-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
1-[(4-butoxyphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[(2,3,5-trichlorophenyl)methyl]-piperidine;  
1-[(2,5-dichlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine;  
4-(1*H*-imidazol-4-ylmethoxy)-1-[[2-(trifluoromethyl)phenyl]methyl]-piperidine, or  
1-[(4-chloro-2-nitrophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine  
[[and]] or a pharmaceutically acceptable salt[[s and]] or solvate[[s]] thereof.